StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a research note published on Saturday. The brokerage issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Down 0.3%
Shares of BTX stock opened at $6.83 on Friday. The firm has a market cap of $401.78 million, a price-to-earnings ratio of -3.01 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52-week low of $5.10 and a 52-week high of $8.31. The company’s 50 day moving average is $6.29 and its 200 day moving average is $3.19.
Brooklyn ImmunoTherapeutics Announces Dividend
The company also recently announced a monthly dividend, which was paid on Monday, March 31st. Shareholders of record on Friday, March 14th were paid a $0.0862 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.03 annualized dividend and a yield of 15.14%. Brooklyn ImmunoTherapeutics’s dividend payout ratio (DPR) is -45.37%.
Brooklyn ImmunoTherapeutics Company Profile
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Featured Stories
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- Do ETFs Pay Dividends? What You Need to Know
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
- Earnings Per Share Calculator: How to Calculate EPS
- What Ray Dalio’s Latest Moves Tell Investors
- How to Use Stock Screeners to Find Stocks
- Amazon: Why May Is the Last Month to Get the Stock at a Discount
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
